8-K: QuidelOrtho Reports Mixed Q4 and Full-Year 2024 Results, Issues 2025 Guidance

QuidelOrtho's Q4 2024 revenue was $708 million, and the company is focusing on cost-saving initiatives to improve adjusted EBITDA margins in 2025 and beyond.

Summary

• QuidelOrtho reported fourth quarter 2024 revenue of $708 million, a decrease from $743 million in the prior year period.
• Non-respiratory revenue was flat at $565 million, while respiratory revenue decreased by 18% to $143 million.
• Full-year 2024 revenue was $2.78 billion, compared to $3.00 billion in the prior year.
• The company reported a GAAP diluted loss per share of $2.28 for Q4 2024 and $30.16 for the full year.
• Adjusted EBITDA for Q4 2024 was $150 million, with a margin of 21%, while full-year adjusted EBITDA was $543 million, with a margin of 19.5%.
• QuidelOrtho is issuing fiscal year 2025 financial guidance, projecting total revenues between $2.60 and $2.81 billion, adjusted EBITDA between $575 and $615 million, and adjusted diluted EPS between $2.07 and $2.57.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company is implementing cost-saving initiatives and providing guidance for 2025, the current results show a significant loss and a decline in revenue compared to the previous year. The reliance on cost savings to improve future performance introduces uncertainty.

Positives

• Labs revenue grew 4% in constant currency, excluding COVID-19 and non-core revenues.
• The company is implementing cost-savings initiatives to improve margins.
• Respiratory revenue increased by 4% as reported and in constant currency, excluding COVID-19 revenue.
• The company has issued full-year 2025 financial guidance.

Negatives

• Fourth quarter revenue decreased to $708 million from $743 million in the prior year.
• Full-year revenue decreased to $2.78 billion from $3.00 billion in the prior year.
• GAAP diluted loss per share for the full-year 2024 was $30.16, compared to $0.15 in the prior year.
• GAAP operating loss for the full-year 2024 was $1.96 billion, which included a non-cash goodwill impairment charge of approximately $1.82 billion, compared to operating income of $139 million in the prior year.
• GAAP operating margin was (70)% for the full-year 2024, compared to 5% in the prior year.

Risks

• Fluctuations in demand for respiratory and non-respiratory products could impact future results.
• Supply chain, production, logistics, distribution, and labor disruptions could pose challenges.
• Integration of Quidel and Ortho Clinical Diagnostics presents challenges and costs.
• Macroeconomic, geopolitical, market, business, competitive, and regulatory factors could affect the business.

Future Outlook

QuidelOrtho expects total revenues between $2.60 and $2.81 billion, adjusted EBITDA between $575 and $615 million, and adjusted diluted EPS between $2.07 and $2.57 for fiscal year 2025.

Management Comments

• Brian J. Blaser, President and Chief Executive Officer, stated that the company is pleased with its 2024 business performance and ended the year with positive momentum leading into 2025.
• Management expects cost-savings initiatives will help the company operate more effectively and deliver incremental margin improvement in 2025 and beyond.

Industry Context

QuidelOrtho operates in the in-vitro diagnostics market, which is influenced by factors such as demand for diagnostic testing, technological advancements, and regulatory changes. The decline in COVID-19 related revenue is a common trend across the industry as the pandemic's impact wanes.

Comparison to Industry Standards

• Companies like Roche, Abbott, and Siemens Healthineers also experienced fluctuations in revenue due to the changing demand for COVID-19 tests.
• QuidelOrtho's focus on cost-saving initiatives aligns with industry trends as companies seek to improve profitability in a post-pandemic environment.
• The projected 22% adjusted EBITDA margin for 2025 is a key metric to watch, as it reflects the success of these cost-saving efforts and positions QuidelOrtho relative to its peers.

Stakeholder Impact

• Shareholders will be concerned about the GAAP losses and revenue decline.
• Employees may be affected by cost-saving initiatives.
• Customers will be interested in the company's ability to continue providing innovative diagnostic solutions.
• Suppliers may be impacted by changes in the company's operations and cost structure.

Next Steps

• The company will hold a conference call to discuss the financial results.
• Investors should monitor the progress of cost-saving initiatives and their impact on future margins.
• The company will continue to execute its strategic goals and financial guidance for 2025.

Key Dates